EUR/USD likely to find a peak near 1.25: UBS
BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near its 52-week high, recently sold shares of the company in a transaction valued at $142,547. According to InvestingPro data, the company’s stock has delivered a 13% return year-to-date. According to a filing with the Securities and Exchange Commission, the sale involved 310 shares at a price of $459.83 each, executed on February 11, 2025. This transaction was conducted under a pre-arranged trading plan approved by the company under Rule 10b5-1, which Ms. Tatsis entered into on February 29, 2024. Following this sale, Tatsis holds 64,021 shares of Vertex common stock. The company maintains strong financial health with a current ratio of 2.69, indicating ample liquidity to meet short-term obligations. Get comprehensive insights and 10 additional key tips about Vertex with an InvestingPro subscription.
In a separate transaction on February 10, 2025, Tatsis disposed of 2,143 shares due to tax obligations, valued at $1,002,881, although this was not a sale on the open market. Vertex Pharmaceuticals, headquartered in Boston, is a prominent player in the biotechnology industry, operating with moderate debt levels and generating annual revenue of $11 billion with an 11.7% growth rate.
In other recent news, Vertex Pharmaceuticals has been the focus of several analyst firms. TD Cowen reaffirmed its Buy rating for Vertex, maintaining a $525 price target, and highlighted the company’s strong fourth-quarter performance with cystic fibrosis (CF) revenues reaching $2.9 billion. Furthermore, the firm projects a compound annual growth rate (CAGR) of 9% in revenue through 2030, driven by Vertex’s maturing pipeline, including the upcoming product Journavx.
Simultaneously, Truist Securities raised the price target for Vertex from $460 to $520, maintaining its Buy rating. The adjustment reflects positive feedback on the launches of Vertex’s drugs Alyftrek and Journavx, with the latter being touted as a potential alternative to opioids.
BMO Capital Markets also maintained its Outperform rating on Vertex, setting a price target of $545. The firm recognized Vertex’s growth potential and portfolio diversification through 2025, largely driven by the launches of Alyftrek and Journavx.
Morgan Stanley (NYSE:MS) adjusted its outlook on Vertex shares, raising the price target from $450 to $459, maintaining an Equalweight rating. This revision follows Vertex’s recent financial performance and guidance update.
Lastly, Scotiabank (TSX:BNS) analyst Greg Harrison updated the price target for Vertex to $450, up from $433, while maintaining a Sector Perform rating. The adjustment follows Vertex’s strong fourth-quarter performance in 2024, with total revenues surpassing consensus. Vertex’s revenue guidance for 2025 is set between $11.75 billion and $12.0 billion, suggesting a high single-digit top-line growth rate. These are some of the recent developments surrounding Vertex Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.